Angiotensin receptor blockers and tumorigenesis: something to be (or not to be) concerned about? (Q37998961)

26 August 2017

Angiotensin receptor blockers and tumorigenesis: something to be (or not to be) concerned about? (English)

1 reference

26 August 2017

2

Gregory Y H Lip

1 reference

26 August 2017

Vadim Tchaikovski

1

1 reference

26 August 2017

1 June 2012

1 reference

Current Hypertension Reports

26 August 2017

1 reference

26 August 2017

14

1 reference

26 August 2017

183-192

1 reference

26 August 2017

3

1 reference

https://scigraph.springernature.com/pub.10.1007/s11906-012-0263-x

26 August 2017

0 references

cites work

Carcinogenicity of cardiovascular drugs.

1 reference

https://api.crossref.org/works/10.1007%2FS11906-012-0263-X

Angiotensin-receptor blockade and risk of cancer: meta-analysis of randomised controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-012-0263-X

Antihypertensive drugs and risk of cancer: network meta-analyses and trial sequential analyses of 324 168 participants from randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-012-0263-X

Effects of telmisartan, irbesartan, valsartan, candesartan, and losartan on cancers in 15 trials enrolling 138,769 individuals

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-012-0263-X

Use of Angiotensin Receptor Blockers and the Risk of Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-012-0263-X

Knocking out angiotensin II in the heart

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-012-0263-X

Angiotensin-(1-7): pharmacological properties and pharmacotherapeutic perspectives

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-012-0263-X

ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-012-0263-X

Impact of acute myocardial ischemia reperfusion on the tissue and blood-borne renin-angiotensin system

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-012-0263-X

The mitochondrial component of intracrine action

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-012-0263-X

Angiotensin II: a hormone involved in and contributing to pro-hypertrophic cardiac networks and target of anti-hypertrophic cross-talks

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-012-0263-X

Captopril reduces cardiac inflammatory markers in spontaneously hypertensive rats by inactivation of NF-kB

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-012-0263-X

Role of angiotensin-converting enzyme inhibitors in vascular modulation: beyond the hypertensive effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-012-0263-X

2009 focused update: ACCF/AHA Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-012-0263-X

Angiotensin I-converting enzyme inhibitors are allosteric enhancers of kinin B1 and B2 receptor function

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-012-0263-X

Angiotensin-converting enzyme is involved in outside-in signaling in endothelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-012-0263-X

Achieving blood pressure goals: should angiotensin II receptor blockers become first-line treatment in hypertension?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-012-0263-X

Comparing angiotensin II receptor blockers on benefits beyond blood pressure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-012-0263-X

Valsartan for prevention of recurrent atrial fibrillation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-012-0263-X

Effects of high-dose versus low-dose losartan on clinical outcomes in patients with heart failure (HEAAL study): a randomised, double-blind trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-012-0263-X

Angiotensin II-induced vasodilation via type 2 receptor: role of bradykinin and nitric oxide

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-012-0263-X

Effects of angiotensin metabolites in the coronary vascular bed of the spontaneously hypertensive rat: loss of angiotensin II type 2 receptor-mediated vasodilation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-012-0263-X

Angiotensin II type 2 receptor stimulation: a novel option of therapeutic interference with the renin-angiotensin system in myocardial infarction?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-012-0263-X

Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-012-0263-X

Telmisartan, ramipril, or both in patients at high risk for vascular events

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-012-0263-X

Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-012-0263-X

Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-012-0263-X

21 January 2018

The Hallmarks of Cancer

1 reference

https://api.crossref.org/works/10.1007%2FS11906-012-0263-X

The angiotensin II/angiotensin II receptor system correlates with nodal spread in intestinal type gastric cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-012-0263-X

Functional expression of the angiotensin II type 1 receptor in human ovarian carcinoma cells and its blockade therapy resulting in suppression of tumor invasion, angiogenesis, and peritoneal dissemination

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-012-0263-X

Blockade of angiotensin AT1a receptor signaling reduces tumor growth, angiogenesis, and metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-012-0263-X

The renin-angiotensin system and malignancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-012-0263-X

Angiotensin receptors: a new role in cancer?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-012-0263-X

Cancer, inflammation and the AT1 and AT2 receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-012-0263-X

Direct stimulation of Jak/STAT pathway by the angiotensin II AT1 receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-012-0263-X

Deficiency or blockade of angiotensin II type 2 receptor delays tumorigenesis by inhibiting malignant cell proliferation and angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-012-0263-X

Induction of apoptosis in leukemic cell lines treated with captopril, trandolapril and losartan: a new role in the treatment of leukaemia for these agents.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-012-0263-X

Dual repressive effect of angiotensin II-type 1 receptor blocker telmisartan on angiotensin II-induced and estradiol-induced uterine leiomyoma cell proliferation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-012-0263-X

Potential role of Renin-Angiotensin-system for tumor angiogenesis in receptor negative breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-012-0263-X

Role of host angiotensin II type 1 receptor in tumor angiogenesis and growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-012-0263-X

Angiotensin type 1a receptor signaling-dependent induction of vascular endothelial growth factor in stroma is relevant to tumor-associated angiogenesis and tumor growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-012-0263-X

Angiotensin II type 2 receptor signaling significantly attenuates growth of murine pancreatic carcinoma grafts in syngeneic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-012-0263-X

Pilot study of angiotensin II receptor blocker in advanced hormone-refractory prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-012-0263-X

Association of ACE inhibitors and angiotensin receptor blockers with keratinocyte cancer prevention in the randomized VATTC trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-012-0263-X

Association between captopril, other antihypertensive drugs and risk of prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-012-0263-X

European studies on long-term exposure to ambient particulate matter and lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-012-0263-X

Asbestos exposure and cancer mortality among petroleum refinery workers: a Poisson regression analysis of updated data.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-012-0263-X

Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-012-0263-X

The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-012-0263-X

Feasibility of treating prehypertension with an angiotensin-receptor blocker

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-012-0263-X

Effect of candesartan on prevention (DIRECT-Prevent 1) and progression (DIRECT-Protect 1) of retinopathy in type 1 diabetes: randomised, placebo-controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-012-0263-X

Effect of candesartan on progression and regression of retinopathy in type 2 diabetes (DIRECT-Protect 2): a randomised placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-012-0263-X

Angiotensin II receptor blocker-based vs. non-angiotensin II receptor blocker-based therapy in patients with angiographically documented coronary artery disease and hypertension: the Heart Institute of Japan Candesartan Randomized Trial for Evaluati

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-012-0263-X

Metabolic outcome during 1 year in newly detected hypertensives: results of the Antihypertensive Treatment and Lipid Profile in a North of Sweden Efficacy Evaluation (ALPINE study).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-012-0263-X

The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-012-0263-X

Mode of death in patients with heart failure and a preserved ejection fraction: results from the Irbesartan in Heart Failure With Preserved Ejection Fraction Study (I-Preserve) trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-012-0263-X

Cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial of patients with type 2 diabetes and overt nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-012-0263-X

A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-012-0263-X

Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-012-0263-X

Telmisartan to prevent recurrent stroke and cardiovascular events

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-012-0263-X

Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-012-0263-X

Effect of valsartan on the incidence of diabetes and cardiovascular events

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-012-0263-X

Valsartan in a Japanese population with hypertension and other cardiovascular disease (Jikei Heart Study): a randomised, open-label, blinded endpoint morbidity-mortality study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-012-0263-X

Effects of valsartan on morbidity and mortality in uncontrolled hypertensive patients with high cardiovascular risks: KYOTO HEART Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-012-0263-X

Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-012-0263-X

Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-012-0263-X

Effect of angiotensin receptor blockers on cardiovascular events in patients undergoing hemodialysis: an open-label randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-012-0263-X

Can antihypertensive drugs increase the risk of cancer?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-012-0263-X

Diuretics and renal cell carcinoma—What is the risk/benefit ratio?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-012-0263-X

The number of lymph node metastases in gastric cancer correlates with the angiotensin I-converting enzyme gene insertion/deletion polymorphism

21 January 2018

1 reference

12 December 2020

Reserpine use in relation to breast cancer

1 reference

12 December 2020

Angiotensin II activates nuclear transcription factor kappaB through AT(1) and AT(2) in vascular smooth muscle cells: molecular mechanisms

1 reference

12 December 2020

Angiotensin II induces apoptosis in vivo in skeletal, as well as cardiac, muscle of the rat

1 reference

12 December 2020

Angiotensin II type I antagonist prevents pulmonary metastasis of murine renal cancer by inhibiting tumor angiogenesis

1 reference

12 December 2020

Impact of angiotensin I converting enzyme inhibitors and angiotensin II type 1 receptor blockers on survival in patients with advanced non-small-cell lung cancer undergoing first-line platinum-based chemotherapy

1 reference

12 December 2020

Antihypertensive medication and their impact on cancer incidence: a mixed treatment comparison meta-analysis of randomized controlled trials

1 reference

12 December 2020

Medical Research Council trial of treatment of hypertension in older adults: principal results. MRC Working Party

1 reference

12 December 2020

Renoprotection of Optimal Antiproteinuric Doses (ROAD) Study: a randomized controlled study of benazepril and losartan in chronic renal insufficiency

1 reference

12 December 2020

Keratinocyte cancer prevention with ACE inhibitors, angiotensin receptor blockers or their combination in renal transplant recipients.

1 reference

12 December 2020

2007 Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC).

1 reference

12 December 2020

Do calcium antagonists cause death, gastrointestinal bleeding, and cancer?

1 reference

12 December 2020

Induction of hypoxia-inducible factor-1alpha by transcriptional and translational mechanisms

1 reference

12 December 2020

Does diuretic therapy increase the risk of renal cell carcinoma?

1 reference

12 December 2020

10.1007/S11906-012-0263-X

Identifiers

DOI

1 reference

26 August 2017

1 reference

PubMed ID

22467342